GenEdit, Inc. focuses on the development of novel, non-viral, nanoparticle-based delivery technology and enabling next generation CRISPR-based gene therapies. The foundation of our CRISPR-Nanoparticle Technology Platform is based on successfully engineering the individual components of the CRISPR system to overcome the limitations of existing delivery vehicles for CRISPR-based therapeutics.

Accounting & Finance

Berkeley, CA, USA

South San Francisco, CA, USA

GenEdit

Biotechnology

Delivery service

Genetics

Therapeutics

	
Bow is a venture capital fund bridging the best of academia, business, and entertainment. We formed to leverage the discoveries of the University of California with the business potential of Silicon Valley and entertainment.

Build a legacy